Navigation Links
Calls to combat deafness after chemotherapy

The Royal National Institute for Deaf people (RNID) has asked drug companies to find ways of reducing the occurrence of deafness among cancer patients who survive chemotherapy. //

The Institute is looking mainly at the effects of the anti-tumor agent cisplatin, which has been successfully used to combat a variety of cancers in adults as well as children. Cisplatin is a platinum-based chemotherapy, which has successfully cured 30 percent of cancers in children and about 25 percent of adult cancers. But it has a major flaw in that it causes tinnitus or ringing in the ears. RNID commercial research manager, Munna Vio said, "Our research indicates that if a suitable drug was approved that effectively protected against hearing loss, but did not interfere with chemotherapy, oncologists would use it across the board for all cancers treated with cisplatin. Thousands of survivors are being left with unnecessary hearing damage."

Drug companies say that such a drug, which blocks the unwanted effects of chemotherapy, is already available. Penelope Brock, a leading British oncologist has also added her voice to this cause, "Permanent side-effects are the most damaging, and hearing loss is one which affects everyday life and development." She feels that with adequate incentive an otoprotectant drug could be on the market within two years.


'"/>




Page: 1

Related medicine news :

1. WHO Calls For Greater Emphasis On Combating AIDS
2. PCT Calls Upon Doctor To Delay Surgeries
3. UN Calls For More Funds For Earthquake Affected
4. MP Calls For Ban On Aspartame
5. Scientist Calls Upon Media To Retract His Work
6. CMHA Calls For Better Trained Police For Dealing With The Mentally Ill
7. US Government Calls For Better Drug Supplies
8. Report Calls For Better Implementation Of Last Wishes of Terminally Ill
9. Mixed Orientation Marriages Calls for Deeper Understanding
10. Rare Sexual Syndrome In Women Calls For More Research
11. Bihar CM Calls For Concerted Efforts To Tackle HIV/AIDS Menace
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... 2017 , ... The StayWell Company announced today that it ... StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, and ... programs for the delivery and improvement of disease management and that meet or ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... training program owned and organized by HMP Communications Holdings, LLC, today announced that ... physicians within its nationwide network of wound centers interested in becoming Certified Wound ...
(Date:3/23/2017)... Collins, CO (PRWEB) , ... March 23, 2017 ... ... firm serving the families and businesses of the greater Fort Collins area, has ... campaign in their ongoing community involvement program. Donations to this worthy cause may ...
(Date:3/23/2017)... York City (PRWEB) , ... March 23, 2017 , ... ... last fall, FaceCradle , the most-funded travel pillow in crowdfunding history, ... speed delivery of its wildly popular travel innovation to Americans. , “We’re excited to ...
(Date:3/23/2017)... ... ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... 43rd President of the United States of America: George W. Bush , ... of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017 Research and Markets has announced the ... to their offering. ... The global capillary electrophoresis market to grow at a CAGR ... Global Capillary Electrophoresis Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:3/23/2017)... 2017 Newborns are highly vulnerable to ... because their young immune systems typically mount weak ... report achieving strong vaccine responses in newborn animals, ... human trials — by adding compounds known as ... simultaneous papers, they also describe improved adjuvant formulations ...
(Date:3/23/2017)... 23, 2017 Prima BioMed has ... trial of IMP321 in combination with Keytruda, with one ... cohort experiencing a complete response. Recruitment in the second ... to be fully recruited by Q317. Preliminary efficacy data ... cancer study are expected mid-year (recruitment in the 226-patient ...
Breaking Medicine Technology: